Zoliflodacin is under clinical development by Entasis Therapeutics Holdings and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Zoliflodacin’s likelihood of approval (LoA) and phase transition for Uncomplicated Cervical And Urethral Gonorrhea took place on 29 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zoliflodacin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Zoliflodacin overview

Zoliflodacin (ETX-0914 (formerly AZD-0914)) is under development for the treatment of drug-resistant uncomplicated cervical and urethral gonorrhea. The drug candidate is administered through oral route as an antimicrobial amorphous nonsterile powder. The drug candidate is a benzisoxazole derivative and it acts by targeting ATP pocket of DNA gyrase and topoisomerase IV.

Entasis Therapeutics Holdings overview

Entasis Therapeutics Holdings (Entasis) is a drug development company. It discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0462 and Zoliflodacin. Its ETX2514 product is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.

Quick View Zoliflodacin LOA Data

Report Segments
  • Innovator
Drug Name
  • Zoliflodacin
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.